• Q2 FY25 revenue of $28.5 million, +19.8% (+19.9% in constant currency) versus pcp
• Cash balance increased to $18.5 million as at 31 December 2024
• FY25 guidance: revenue of ~$105 million, EBITDA of $7-9 million, capex of $3-4 million

SomnoMed Limited (ASX 'SOM' or the Company), the leading company in the provision of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea (OSA), has released its quarterly activities report for the period ended 31 December 2024 (Q2 FY25). The Company reported Q2 FY25 revenue of $28.5 million, an increase of 19.8% (+19.9% in constant currency) versus the previous corresponding period (pcp). The cash balance increased to $18.5 million as at 31 December 2024. The Company has provided an update to its FY25 guidance, with revenue expected to be approximately $105 million, EBITDA between $7 million to $9 million, and capex of between $3 million to $4 million. This updated guidance considers the strong growth in the first half of FY25, which is expected to continue, although growth may slow in the remaining quarters as order backlog is cleared. The Company continues to work on efficiencies alongside budgeted operational and personnel investments during the second half of FY25. The quarterly report also highlights the Company's progress, including strong revenue growth in all geographies, particularly North America, and ongoing collaboration with a manufacturing consultancy to further increase production capacity and efficiency.

Revenue of approximately $105 million, EBITDA of between $7 million to $9 million, and capex of between $3 million to $4 million for FY25.